Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a research report sent to investors on Saturday.

TBPH has been the subject of several other reports. Jones Trading upgraded shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 price target for the company in a research report on Tuesday, June 17th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

Theravance Biopharma Trading Down 0.6%

TBPH stock opened at $10.57 on Friday. The company’s 50 day moving average is $9.82 and its 200 day moving average is $9.48. The stock has a market cap of $528.50 million, a price-to-earnings ratio of -8.96 and a beta of -0.09. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.82.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $28.08 million. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. As a group, sell-side analysts forecast that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 24,000 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the transaction, the senior vice president now directly owns 336,918 shares in the company, valued at $3,706,098. The trade was a 6.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Aquatic Capital Management LLC purchased a new position in Theravance Biopharma in the 4th quarter worth about $25,000. GAMMA Investing LLC increased its position in Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 3,281 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Theravance Biopharma during the 4th quarter valued at about $69,000. Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma during the 4th quarter valued at about $103,000. Finally, AQR Capital Management LLC bought a new position in Theravance Biopharma in the first quarter worth approximately $101,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.